March 6, 2023
Won’t change much.
This morning Abbott received word that the FDA has cleared the Libre 2 and Libre 3 for integration into an automated insulin dosing (AID) system. Per their press release –
“Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems.”
It should be noted that the current Libre 2 and Libre 3 sensors have NOT been cleared and modified versions of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
